INTRODUCTION

The COVID-19 pandemic has caused unprecedented health and socioeconomic challenges. The number of children infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gradually increased since the start of the pandemic. Going back to school after lockdown, continuing to get routine vaccinations and going outdoors have all been severely affected. Jones et al. showed that the viral load of asymptomatic children with COVID-19 was the same, or higher, than that of symptomatic children or adults. The load was closely related to their infectivity, which suggested that children and adults were equally infectious. COVID-19 measures, such as quarantining, timely nucleic acid testing and wearing masks, have been implemented in many countries. These include China, which has now entered a period of normalised prevention, control and management of the COVID-19 pandemic.

Although relevant basic and clinical research has been gradually increased, awareness of the aetiological, epidemiological and clinical characteristics of SARS-CoV-2 has also continuously improved. Meanwhile, relevant prevention and control plans and diagnosis and treatment recommendations have been continuously revised and improved. However, preventing and controlling the SARS-CoV-2
infection is still a matter of global concern.\textsuperscript{1,3} This is due to huge differences in factors such as people’s values, cultures, traditions, mobility and disease control measures, and how intensely they are implemented. In general, diagnoses, fatalities and immunity levels have been low in children, but they have proved highly infectious and the transmission route has been relatively wide. SARS-CoV-2 endangers public health safety, damages the physical health of infected children and affects their psychological and spiritual health.\textsuperscript{4} Measures such as nucleic acid testing, quarantining and wearing masks can effectively curb the spread of the virus in the short term. However, in the long run, vaccination is the way for the population to obtain specific immunity to the virus and is the most effective way to prevent the spread of the virus.\textsuperscript{3} The World Health Organization (WHO) established the COVID-19 Vaccines Global Access Facility on 15 July 2020 and 187 countries were members by 16 April 2020. On 16 November 2020, the WHO published interim guidelines to help governments formulate and update national deployment and vaccination plans.\textsuperscript{5} However, due to uncertainties about the safety and efficacy, parents remained neutral about whether children should be vaccinated and children had not begun to receive the COVID-19 vaccine widely by 16 April 2021.\textsuperscript{6} This paper reviews the challenges of providing children with COVID-19 vaccines, covering aspects such as epidemiology, vaccine development, the current status of children vaccination at the time of writing and the benefits and disadvantages of vaccination to children, parents and society.

2 | METHODS

We searched English and Chinese medical databases for relevant papers published between 10 February 2020 and 14 July 2021. The English databases included PubMed, Elsevier Scopus, Web of Science, Embase, Google Scholar and Science Direct. The Chinese databases included CNKI, WanFangData, CQVIP and CBM. The keywords that were used were: coronavirus disease 2019, COVID-19, 2019-nCoV, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, mutant, vaccine, COVID-19 vaccine, vaccine coverage, vaccination, vaccine, safety, efficacy, children, epidemiological characteristics, clinical characteristics, multisystem inflammatory syndrome in children, MIS-C, long-term symptoms of COVID-19, long COVID, parental acceptance and herd immunity. Relevant papers published in English or Chinese on routine immunisation regimens during the COVID-19 pandemic were included. We also researched a range of key websites, including the WHO, American Academy of Pediatrics, Gavi, the United States Centers for Disease Control and Prevention, the Bloomberg COVID-19 vaccine tracker and the University of Oxford. These provided information on the epidemiological characteristics of COVID-19 in children from different countries, progress on vaccine research, including paediatric participants, where children were actually being vaccinated and the transmissibility of the virus and the severity of different mutations. EndNoteX9 (Clarivate Analytics, Philadelphia, USA) was used to manage the references, and bibliometrics and various statistical descriptions. Other methods were used to analyse the distribution of the basic clinical elements of the study. Keyword analysis and abstract subject analysis were used to describe research and vaccination progress, including the clinical status of children who had received the vaccine or participated in vaccine trials and the challenges they faced. Bibliometrics were used to analyse the country or region of the study and the characteristics of the study subjects. Statistical descriptions and distribution charts were used to evaluate and demonstrate, the children’s epidemiological characteristics and the safety, efficacy and parental acceptance of vaccine. This process enabled us to summarise the key findings of 44 academic papers and 16 news items.

3 | RESULTS

3.1 | Prevalence and challenges of COVID-19 in children

SARS-CoV-2 is a universally susceptible global virus and children of all ages are affected, with no obvious gender differences. Since the outbreak started there have been many reports about paediatric cases.\textsuperscript{1,3} State-level data from the American Academy of Pediatrics showed that by 8 April 2021, children in the United States accounted for 5.30%–32.30% of virus positive cases in the country and 0.10%–1.90% of infected children were hospitalised. Children also accounted for 0.00%–0.19% of COVID-19 deaths\textsuperscript{4} (Table 1).

A study from Wuhan reported that infants up to 1 year of age were 2.20 times more likely to be infected with SARS-CoV-2 than children aged 2–5 years and 1.53 times more likely than children aged 6–12 years. In addition, individuals under the age of 20 were 1.58 times more likely to spread the virus to others than adults over 60.\textsuperscript{7} Children with COVID-19 tended to be characterised by cluster infections. For example, Yoon et al. identified the percentage of children with COVID-19 who had been infected by family members in Korea. It was 78.3% of children aged 0–9 years and 23.8% of children aged 10–19 years.\textsuperscript{8}
Studies have also showed that, although most children have had mild COVID-19, there have also been many severe cases. According to an American study by Feldstein et al., about one-third of children who were nucleic acid-positive for SARS-CoV-2 were admitted to intensive care units. So were up to 80% of children with multisystem inflammatory syndrome in children (MIS-C), which is a clinical syndrome related to COVID-19. The United States Centers for Disease Control and Prevention found that many of the children with MIS-C had serious complications, including heart inflammation and kidney damage. Nearly two-thirds of those children were admitted to intensive care units for an average of 5 days. By 29 March 2021, 3,185 children in the USA had been diagnosed with MIS-C and 36 had died. Buonsenso et al. studied 129 Italian children with COVID-19, at an average of 162.5 ± 113.7 days after diagnosis. They found that 41.8% of diagnosed children fully recovered, 35.7% had one or two symptoms and 22.5% had three or more symptoms. The most commonly reported symptoms were: insomnia (18.6%), respiratory symptoms, including pain and chest tightness (14.7%), nasal congestion (12.4%), fatigue (10.8%), muscle and joint pain (6.9%) and difficulty concentrating (10.1%). Swedish case studies of children with long COVID-19 showed fatigue, dyspnoea, palpitations or chest pain 60 days after their initial diagnosis and all five had persistent symptoms six months later.

Ng et al. found that 5.3% of 302 adults who were not infected with SARS-CoV-2 carried immunoglobulin G antibodies that could bind to the virus. However, protein reactive immunoglobulin G antibodies could not be detected in 43.8% of the 48 who were virus free. A Canadian study that analysed data from more than 200,000 COVID-19 cases, and was published in July 2021, reported that the Alpha, Beta and Gamma variants were associated with a greater surge in virulence and transmissibility than non-variants of concern. These variants also increased the risk of hospitalisation, intensive care admissions and death by 59%, 105% and 61% respectively. They also increased the probability of children being infected.

The COVID-19 pandemic has had a negative impact on children’s education, emotional health and social development. Anderson et al. showed that rotavirus, varicella and other conventional vaccines significantly reduced the mortality rate of children with those diseases in the United States. The authors added that the number of deaths of children with COVID-19 in 1 year was rapidly approaching that level and would surpass the number of child deaths related to influenza from 2016 to 2020.

Therefore, children should be vaccinated against COVID-19 to prevent the pandemic from harming children, families and society.

### 3.2 The COVID-19 vaccine and child vaccination

The global COVID-19 vaccine development is based on seven key technical vaccine routes: inactivated, virus-like particle, protein subunit, virus-vector, deoxyribonucleic acid, messenger ribonucleic acid and live-attenuated. Most of the current vaccines target the spike protein, glycprotein S, and its variants. The structure and function of SARS-CoV-2 glycoprotein S are similar to highly pathogenic Beta coronaviruses, such as Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. Glycoprotein S comprises two subunits. S1 contains a receptor binding domain that interacts with the angiotensin-converting enzyme 2 receptor on the cell surface. S2 mediates the fusion of the virus membrane and cell membrane by forming a six-helix bundle fusion core. In order to prevent SARS-CoV-2 infections, it is very important to form neutralising antibodies against the S1 receptor binding domain and the S1 N-terminal domain. These antibodies can block the binding of the receptor binding domain to the angiotensin-converting enzyme 2 receptor and prevent S2-mediated membrane fusion or entry into the host cells, thereby inhibiting the virus infection.

By 16 April 2021, 14 COVID-19 vaccines had been approved worldwide: five from China, three from Russia, two from India, two from the United States, one from Germany and one from the UK. Of those, two are messenger ribonucleic acid vaccines, five are inactivated virus vaccines, five are non-replicating virus vector vaccines and two are protein subunit vaccines. In addition, 102 vaccines were already undergoing clinical trials: 30 phase I, 42 phase II and 30 phase III. State-level data from the American Academy of Pediatrics showed that by 14 July 2021, 6.8 million children in the USA were fully vaccinated: 38% aged 16–17 years and 25% aged 12–15 years. Meanwhile, 8.8 million American children under the age of 18 had received at least one dose of the COVID-19 vaccine: 46% aged 16–17 years and 34% aged 12–15 years.

The development of children’s COVID-19 vaccines has been slow, but the non-replicating nature of the AstraZeneca vaccine makes it

### Table 1 COVID-19 pandemic status of children in different countries

| Country (2021 end date) | Children as a percentage of total cases (%) | Children as a percentage of total hospital admissions (%) | Children as a percentage of total hospital deaths (%) |
|------------------------|---------------------------------------------|----------------------------------------------------------|--------------------------------------------------------|
| USA4 (8 April)          | 13.50                                       | 1.30–3.00                                                | 0.00–0.03                                              |
| Canada50 (9 April)      | 17.70                                       | 1.70                                                    | 0.00                                                   |
| Sweden50 (15 April)     | 14.08                                       | 1.06                                                    | 0.00–0.10                                              |
| Spain50 (14 April)      | 12.70                                       | 3.40                                                    | 0.00                                                   |
| New Zealand51 (18 April)| 13.50                                       | 3.12                                                    | 0.00                                                   |
| Italy50 (7 April)       | 14.10                                       | /                                                       | 0.00                                                   |
| China52 (16 April)      | 2.10                                        | /                                                       | 0.10                                                   |
| Type          | Basic information on vaccines<sup>18</sup> | Progress<sup>18</sup>                                                                                      | Dosing and overall vaccine efficacy (%) | Dosing and vaccine efficacy (moderate or severe cases) (%) | Total incidence of adverse events (%) | Serious incidence of adverse events (%) | Most common adverse reactions |
|--------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------|----------------------------------------|----------------------------------------------------------|--------------------------------------|---------------------------------------|-----------------------------|
| **Protein subunit** |                                          |                                                                                                             |                                        |                                                          |                                      |                                       |                             |
| FBRI         | EpiVacCorona                              | Approved in 2 countries and 3 trials in 1 country                                                           | 2 doses 21 days apart: 95.00<sup>53</sup> | /                                                        | /                                    | /                                     |                             |
| Anhui Zhifei | Longcom receptor binding domain-Dimer     | Approved in 2 countries and 6 trials in 5 countries                                                         | /                                      | /                                                        | 3 doses 30 days apart: 48.00<sup>54</sup> | 3 doses 30 days apart: 3.00<sup>54</sup> | 3 doses 7 days apart: 30.00<sup>54</sup> | 3 doses 7 days apart: 10.00<sup>54</sup> |
| **RNA**      |                                          |                                                                                                             |                                        |                                                          |                                      |                                       |                             |
| Moderna      | mRNA−1273                                 | Approved in 46 countries and 14 trials in 3 countries                                                        | 2 doses 21 days apart: 94.00<sup>53</sup> | 2 doses 21 days apart: 94.00<sup>53</sup> | 2 doses 21 days apart: 100.00<sup>53</sup> | 2 doses 21 days apart: 2.20<sup>55</sup> | 2 doses 21 days apart: 81.90<sup>56</sup> | 2 doses 21 days apart: 74.80<sup>56</sup> |
| BioNTech/Pfizer | BNT162b2                               | Approved in 82 countries and 17 trials in 12 countries                                                       | 2 doses 21 days apart: 95.00<sup>53,57</sup> | /                                                        | 2 doses 21 days apart: 1.95<sup>55</sup> | 2 doses 21 days apart: 0.027<sup>55</sup> | 2 doses 21 days apart: 68.60<sup>56</sup> | 2 doses 21 days apart: 64.20<sup>56</sup> |
| **Non replicating viral vector** |                                          |                                                                                                             |                                        |                                                          |                                      |                                       |                             |
| CanSino      | Ad5-nCoV                                  | Approved in 5 countries and 6 trials in 6 countries                                                          | 1 dose 28 days apart: 65.28<sup>58</sup> | 1 dose 28 days apart: 70.40<sup>59</sup> | 1 dose 28 days apart: 76.00<sup>29</sup> | 1 dose 28 days apart: 1.00<sup>58</sup> | /                                      |                             |
| Gamaleya     | Sputnik V                                 | Approved in 62 countries and 19 trials in 6 countries                                                         | 2 doses 21 days apart: 95.00<sup>53,57</sup> | 2 doses 21 days apart: 94.00<sup>29</sup> | 2 doses 21 days apart: 76.00<sup>29</sup> | 2 doses 21 days apart: 1.00<sup>58</sup> | /                                      |                             |
| Oxford/AstraZeneca AZD1222 | UK ≥ 16                      | Approved in 91 countries and 24 trials in 15 countries                                                       | 2 doses 21 days apart: 70.40<sup>59</sup> | 2 doses 21 days apart: 94.00<sup>29</sup> | 2 doses 21 days apart: 76.00<sup>29</sup> | 2 doses 21 days apart: 1.00<sup>58</sup> | /                                      |                             |
| Serum Institute of India Covishield | India ≥ 18                       | Approved in 33 countries and 2 trials in 1 country                                                          | /                                      | /                                                        | /                                    | /                                     | /                                      |                             |
| Janssen (Johnson & Johnson) Ad26.COV2.S | USA ≥ 18                        | Approved in 40 countries and 7 trials in 17 countries                                                       | 1 dose 28 days apart: 72.00<sup>57</sup> | 1 dose 28 days apart: 72.00<sup>57</sup> | /                                    | /                                     | /                                      |                             |
| **Inactivated** |                                          |                                                                                                             |                                        |                                                          |                                      |                                       | /                                      |                             |
| Bharat Biotech Covaxin | India 12–65               | Approved in 6 countries and 5 trials in 1 country                                                           | /                                      | /                                                        | /                                    | /                                     | /                                      |                             |
| Sinopharm (Beijing) BBIBP-CorV   | China ≥ 18                     | Approved in 35 countries and 6 trials in 7 countries                                                        | 2 doses 28 days apart: 79.34<sup>58</sup> | 2 doses 7 days apart: 1.02<sup>29</sup> | /                                    | /                                     | /                                      |                             |

(Continues)
TABLE 2

| Type | Dosing and vaccine efficacy | Total incidence of adverse events (%) | Serious incidence of adverse events (%) | Local (%) | Systemic (%) |
|------|-----------------------------|--------------------------------------|----------------------------------------|-----------|--------------|
| Sinopharm (Wuhan) | Inactivated (Vero Cells) | 2 doses 28 days | 2 doses 7 days apart: 0.46% | 0.46% | 1.02% |
| China | ≧ 18 | / | / | / | / |
| Sinovac | CoronaVac | 2 doses 28 days | 2 doses 21 days apart: 0.00% | 0.00% | 1.04% |
| China | ≧ 18 | / | / | / | / |
| Chumakov Center | KoviVac | 2 doses 21 days apart: 0.00% | 0.00% | 1.04% | / |
| Russia | ≧ 18 | / | / | / | / |

Note: Data available at: 17/02/2021, 18/02/2021, 21/02/2021, 24/02/2021, 28/02/2021, 01/04/2021, 04/04/2021, 09/04/2021, 12/04/2021, 14/04/2021, 16/04/2021.

The American Academy of Pediatrics has recommended that children aged 16 plus who meet priority group criteria are vaccinated and the organisation has continued to encourage vaccine manufacturers to include young children in their trials to determine safety and efficacy. By February 2021, Pfizer had included children under the age of 12 in clinical trials and Moderna had included adolescents aged 12-17 years. Another study stated that Pfizer had provided two doses, 21 days apart, for individuals aged 16 plus, while Moderna had trialled two doses, 28 days apart, for those aged 18 plus. In April 2021, Mahase published the results of a phase III trial of 2260 children aged 12-15 years in the USA and reported that the preliminary results indicated that the Pfizer vaccine had shown 100% efficacy. The vaccine elicited robust antibody responses and was well tolerated and the side effects were consistent with those observed in participants aged 16-25 years. They have also launched a vaccine trial that will assess the safety, tolerability and immunogenicity of the vaccine in three age groups: 6 months to 2 years and 2-5 and 5-11 years.

Relatively safe for children. The manufacturers included children up to 12 years of age in the second phase of its clinical trials. On 23 January 2021, Israel began to vaccinate children aged 16-18 years with the Astra Zeneca vaccine and by 10 March approximately 600 children under 16 with underlying diseases had also been vaccinated. Previous Astra Zeneca vaccine trials in adults had indicated that it was safe, could produce a strong immune system response and had high efficacy. A UK study was launched on 12 February 2021 to assess if healthy children aged 6–17 years had a good immune response to the Astra Zeneca vaccine. It is being carried out by the University of Oxford and three partner sites in London, Southampton and Bristol. The study has recruited 300 children aged 6–17 years. They gave 240 children the same vaccine dose as the adults and the other 60 formed the control group and received the meningitis vaccine group. The results had not been published at the time of writing. By 16 January 2021, the manufacturers of the Chinese Sinopharm CNBG COVID-19 vaccine had already finished Phase I and II clinical trials on children aged 3–5, 5–12 and 12-17 years, having completed previous clinical trials on those aged 17–59 and 60 plus. The safety data for children aged 3–17 years showed good results and immunogenicity data. This vaccine is expected to cover all patients over the age of 3 years. In June 2021, Sinovac and Hebei Provincial Center for Disease Control and Prevention jointly published the results of a clinical trial that evaluated the clinical results of the CoronaVac in healthy children aged 3-17 years. This was the first study to report the results of an inactivated SARS-CoV-2 vaccine in children. The results showed that CoronaVac was well tolerated and safe and induced humoral responses in children and adolescents aged 3-17 years. In addition, it indicated that children had a higher immune response after vaccination than adults, but this also meant that they were more likely than adults to develop immune overreactions, such as fever and allergies. This highlights the need to balance the protective immune response and side effects when children are vaccinated. In addition, the children under 12 years of age were at a critical stage of their growth and development and the long-term impact of vaccines on children's development should be carefully evaluated.
Children have not yet been universally vaccinated, as the vaccine development and testing time has been relatively short. However, the results of phase III clinical trials of various vaccines are now available, as well as details of adverse reactions in adults and smaller numbers of children. The question remains: is it safe for children to be vaccinated against the virus?

Studies have shown that most of the adverse events from vaccines against SARS-CoV-2 have been mild to moderate and resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, have positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended. Studies have shown that most of the adverse events from COVID-19 vaccines are resolved within 24 h. The immune response to vaccines, and the incidence of adverse reactions, has positively correlated with the dose of vaccine. The most common local adverse reactions that have been reported have been pain, redness and swelling or itching at the injection site. The most common systemic adverse reactions have been fatigue, fever, headache, cough, myalgia, chills, nausea, vomiting and diarrhoea. This shows that most vaccines provide good effectiveness and safety and double-dose vaccinations have been recommended.
a few people were left with impaired heart muscle, so the benefits of vaccination clearly outweigh the risks.30

Some adults have experienced adverse events or even serious adverse events after vaccination and more clinical safety assessments are needed before children are fully vaccinated.

On 20 April 2021, the WHO stated that three main variants of SARS-CoV-2 had emerged. The Alpha variant had been reported in 125 countries by that date. There was no difference in the neutral response of the recovered plasma in this strain and the initial SARS-CoV-2 strain, so it did not affect the efficacy of the existing vaccine.32 The Beta variant had been found in 67 countries by that date and has been associated with a higher viral load that might increase infectivity.32 Wang et al. showed that the Beta variant can escape the effect of neutralising antibodies, so the protective ability of the vaccine might be reduced. The antibodies induced by the Moderna and Pfizer vaccines have been shown to slightly decrease the neutralising activity of the Beta variant, indicating that these vaccines might need to be updated regularly to prevent loss of clinical efficacy.33 The Gamma variant had circulated in 43 countries by that date and the efficacy of the vaccine was still being evaluated.32

A systematic review by Xing et al. showed that the 28d seroconversion rate in COVID-19 subjects was more than 80% in 10 studies. In two clinical trials each with a 10,000-scale, the vaccine efficacy was 95% and 70.4% respectively.28 Huang et al. reported that more than three-quarters of 1733 COVID-19 inpatients in Wuhan Jinyintan Hospital still had at least one persistent symptom 6 months after discharge. The authors also reported that 52.5% of the 94 patients who had undergone an immune response test during the peak of infection only had half the neutralising antibody titres after 6 months, which might make re-infection possible.34

Liu et al. analysed eight children with COVID-19 and found that three of them had neutralising antibodies in their serum during the acute phase, with all eight demonstrating them during the recovery period. This indicates that humoral immunity might play a more critical role in the rehabilitation of children than adults. However, the children continued to shed the virus after producing neutralising antibodies, indicating that the neutralising antibodies produced in the acute phase were not enough to clear SARS-CoV-2 quickly. Clearing the virus might require the production of high-titre neutralising antibodies. The children’s specific antibody response to SARS-CoV-2 was mainly limited to the immunoglobulin G anti-S antibody and the overall level of neutralising activity was lower than adults.35

The efficacy of existing vaccines needs to be further studied, as variants have been discovered in many countries, leading to a further increase in the number of infections.

3.4 Parental acceptance of the SARS-CoV-2 vaccine

Parents usually make decisions about vaccinating children under the age of 18. A study by Bell et al. from 19 April to 11 May 2020 showed that 48.2% of UK parents wanted their children to be vaccinated against COVID-19. 48.3% were uncertain and 3.4% would refuse.36 Goldman et al. surveyed 16 paediatric emergency departments across the USA, Canada, Israel, Japan, Spain and Switzerland from 26 March to 31 May 2020. They found that 65% of parents planned to vaccinate their children against the virus, 33% did not and 2% did not answer. The main reason for vaccination was to protect their children (62%) and the main reason for refusing vaccination was that it would be a new vaccine (52%).37 The fact that most of the parents wanted their children to be vaccinated might have been related to specific factors, such as the demographics and the vaccination histories of the children and parents.37 An online survey by Zhang et al., carried out between 1 September 2020 and 7 September 2020 found that 72.6% of Chinese parents would let their child be vaccinated.38 A study by Jeffs et al. in New Zealand, from 8 May 2020 to 18 May 2020, showed that 60.5% of parents expressed some degree of concern that their child would catch the virus at school and 14.5% of them were very worried. The majority (79.0%) believed that if community transmission was widespread, children were likely to be infected with the virus at school. Most of them (69.6%) said they would let their child be vaccinated and 28.9% would refuse.39 Yigit et al. carried out a study in Ankara City Hospital, Turkey, and stated that 28.9% of parents would let their child receive foreign vaccines, but 56.8% would agree to domestic vaccines.40 Goldman et al. studied 17 paediatric emergency departments across the USA, Canada, Israel, Japan, Spain and Switzerland from 27 March 2020 to 30 June 2020 and found that only 18.4% of parents were willing to let children participate in clinical vaccine trials and the rest were unwilling. However, only 78.3% of those 18.4% parents would agree if it was a randomised controlled trial (Table 3). The most common reasons for refusal were uncertainties about the safety, efficacy and benefits. They were concerned about the side effects and their trust in vaccines from other countries was low. Parents from low-income families were more likely to refuse vaccination. Frequent interactions with medical institutions, such as chronic diseases or regular medication, did not increase parents’ willingness to let children participate in vaccination trials. However, parents were more likely to agree if they trusted the medical system, had a medical or scientific background and their children were already receiving other vaccines in line with their country’s immunisation programmes. These parents felt that vaccine trials were safe and would protect their children. Randomised designs reduced parental agreement.41

A paper by Whibley on the global upsurge in measles in 2018, and a major survey of 140 countries carried out in the same year, showed breath-taking variations in vaccine hesitancy.42 In order to increase parental acceptance, it is necessary to highlight the risks and consequences of the virus and the safety and efficacy of the vaccines, including the transparency of the development process and safety testing. Any parental education and guidance should also deal with misinformation in a timely manner.36,40

3.5 The direct and potential benefits of child vaccination

Savulescu et al. reported that the fatality rate for influenza in the UK and USA was more than one per 1,000,000 if children were not
vaccinated and less than one per 25,000,000 if they were.\textsuperscript{20} Li et al. found that vaccinations had reduced deaths from 10 pathogens by 57% in children under 5 years of age: hepatitis B virus, Haemophilus influenzae type B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, Streptococcus pneumoniae, rotavirus, rubella and yellow fever. This figure was expected to increase to 77% from 2020 to 2030, which would prevent 120 million deaths among under-fives born during that 10-year period.\textsuperscript{42} COVID-19 is similar to flu in this respect and children need to be vaccinated as it is not clear which children have a higher risk of serious and potentially life-threatening diseases.

In addition to direct medical benefits, being vaccinated against the virus could provide children with better life and learning benefits. The pandemic may have caused over a million child deaths due to significantly reduced access to food, interrupted basic health services, missed growth monitoring, and lack of preventive care and timely management of acute diseases and injuries.\textsuperscript{44} During the pandemic, the most vulnerable children have included those separated from their caregivers.\textsuperscript{45} Statistics on previous health-related disasters showed that as many as 30% of children met the criteria for post-traumatic stress disorder.\textsuperscript{45} In addition schools had closed in more than 190 countries around the world by 13 April 2020 and 40 countries were still affected by those restrictions on 31 July 2020. This affected 1.57 billion children, which equated to 90% of the world’s students.\textsuperscript{8} School closures have exacerbated the learning gap, due to inequalities in digital access, with poor children falling further behind.\textsuperscript{46} In addition, social distancing and lack of extra-curricular activities, such as sport, drama, music, art and social activities, have also affected children’s emotional and psychological development.\textsuperscript{15} Ludvigsson found that children with COVID-19 exhibited characteristics of family-aggregated infections, which was same as children with influenza. But this did not mean that school closures would reduce the transmission of SARS-CoV-2. The author also pointed out that school closures had an impact on the daily lives of children, including lack of education, and had an even more severe impact on vulnerable and disadvantaged children.\textsuperscript{46} These findings indicate that child vaccination might have a positive and profound impact on health and equal education.\textsuperscript{15} Vaccines are cost-effective health interventions. They provide direct protection for individuals and have a significant impact on public health safety when high coverage rates are achieved. They can also provide herd immunity for unvaccinated individuals.\textsuperscript{43}

Vaccinating children against Streptococcus pneumoniae, rubella, influenza, rotavirus and hepatitis A has been clearly proven to provide community protection.\textsuperscript{37} Similarly, although children are less likely to suffer severe COVID-19, they may spread the virus to more vulnerable adults at home or in schools. Vaccination would protect them and help to reduce community transmission.\textsuperscript{2} Anderson et al. found that American school closures were temporarily linked to an overall decline in COVID-19 morbidity and mortality.

The pandemic has had a major impact on employment and caused a decline in the global economy. School closures and children’s health have been closely related to whether parents can work. For example, one study found that children’s health was of great significance to economic recovery and reducing family pressure or burden.\textsuperscript{15} Anderson et al.’s review of vaccine trials found that it was difficult to achieve 100% efficacy. They stated that if the R number was 2.5–3.5, and vaccine efficacy was 80%, about 75%–90% of people would need to be vaccinated to achieve herd immunity.\textsuperscript{48} On 7 February 2021, the head of the Israeli Public Health Service stated that one-third of the 9.3 million people in Israel had received at least one vaccine dose and one in five had received two doses. However, there were 2.5 million children in Israel who could not be vaccinated and that, even if all the adults were vaccinated, Israel might not be able to achieve herd immunity.\textsuperscript{49} Since children account for nearly a quarter of the world’s population, effective herd immunity requires children to be vaccinated against the SARS-CoV-2 virus.

4 | CONCLUSION

The key findings of this review were that data on children COVID-19 vaccination were limited, as most of the activity has focused on adults. More clinical trials are needed to assess the safety and efficacy of vaccinating children, as higher vaccination levels can help to build up herd immunity. However, there are wide variations in the percentage of parents who would be willing to have their children vaccinated. Furthermore, we still do not know the full impact that the COVID-19 pandemic will have on children’s lives and learning, public health safety and their parents’ ability to work and support the economy. However, there is no doubt that the consequences will be felt many years to come. Therefore, protecting children from the SARS-CoV-2 infection is both a moral obligation and a practical need. If the vaccine is safe and effective for children, then it should be provided as soon as possible.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

ORCID

Jiatong She \textsuperscript{https://orcid.org/0000-0002-2474-2709}

lanqin Liu \textsuperscript{https://orcid.org/0000-0001-8379-6240}

Wenjun Liu \textsuperscript{https://orcid.org/0000-0002-7205-0598}

REFERENCES

1. She J, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. J Med Virol. 2020;92(7):747-754.
2. Jones TC, Biele G, Muhlemann B, et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science. 2021;373(6551):eabf5273. 10.1126/science.abf5273.
3. Zhou L, Wu Z, Li Z, et al. One Hundred days of coronavirus disease 2019 prevention and control in China. Clin Infect Dis. 2021;72(2):332-339.
4. American Academy of Pediatrics Children and COVID-19: State Data Report. 2021. Accessed April 8, 2021. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/
5. Gavi. COVAX Facility convenes first meeting of COVAX AMC engagement group. 2020. Accessed November 20. https://www.gavi.org/news/media-room/covax-facility-convenes-first-meeting-covax-amc-engagement-group

6. Bhuiyan MU, Stiboy E, Hassan MZ, et al. Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis. Vaccine. 2021;39(4):667-677.

7. Li F, Li YY, Liu MJ, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. Lancet Infect Dis. 2021;21(5):617-628.

8. Yoon Y, Kim KR, Park H, Kim S, Kim YJ. Stepwise school opening and an impact on the epidemiology of COVID-19 in the children. J Korean Med Sci. 2020;35(46):e414.

9. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334-346.

10. The United States Centers for Disease Control and Prevention. 2021. Accessed March 29, 2021. https://www.cdc.gov/mis/cases/index.html

11. Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on the United States Centers for Disease Control and Prevention. 2021. Accessed February 25, 2021. https://www.cdc.gov/coronavirus/2019-ncov/clinical-guidance/children.html

12. Li F, Li YY, Liu MJ, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. Lancet Infect Dis. 2021;21(5):617-628.

13. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339-1343.

14. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada [published online ahead of print July 12, 2021]. medRxiv. 2020;11011(2021):21260050.

15. Anderson EJ, Campbell JD, Creech CB, et al. Warp speed for clinical COVID-19. Acta Paediatr. 2021;110(3):914-921.

16. Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(10):667-668.

17. Logunov DY, Dolzhikova IV, Shchelbyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681.

18. Bloomberg COVID-19 VACCINE TRACKER. 2021. Accessed April 16, 2021. https://www.coronatrackvaccines.org/vaccines/

19. American Academy of Pediatrics. Summary of data publicly reported by the Centers for Disease Control and Prevention. 2021. Accessed July 14, 2021. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-vaccination-trends/

20. Savulescu J, Giubilini A, Danchin M. Global ethical considerations regarding mandatory vaccination in children. J Pediatr. 2021. [published online ahead of print January 20, 2021]. 10.1016/j.jpeds.2021.01.021

21. Wangyi net. Is Israel close to herd immunity? Experts: Vaccination of children is a priority for the future. 2021. Accessed April 6, 2021. https://www.163.com/dy/article/G6T8V80KJ0519D92.html?from=post2020_dy_recommend

22. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144(6):471-484.

23. World Health Organization. COVID-19 Weekly Epidemiological Update. Geneva, Switzerland: World Health Organization; 2021. Accessed April 20, 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-2021-04-20

24. Yuan ZN, Zhao YY, Li L, et al. Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use. Chinese Journal of Epidemiology. 2021;42:1-6.

25. Wise J. Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? BMJ. 2021;373:n635.

26. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144(6):471-484.

27. Mahase E. Covid-19: Pfizer reports 100% vaccine efficacy in children. 2021. Accessed April 20, 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-2021-04-20

28. Xing K, Tu XY, Liu M, et al. Efficacy and safety of COVID-19 vaccines: a systematic review. Chin J Contemp Pediatr. 2021;23(3):221-228.

29. Yang ZN, Zhao YY, Li L, et al. Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use. Chinese Journal of Epidemiology. 2021;42:1-6.

30. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144(6):471-484.

31. Anderson EJ, Campbell JD, Creech CB, et al. Warp speed for clinical COVID-19. Acta Paediatr. 2021;110(3):914-921.

32. World Health Organization. COVID-19 Weekly Epidemiological Update. Geneva, Switzerland: World Health Organization; 2021. Accessed April 20, 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-2021-04-20

33. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616-622.

34. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232.

35. Liu P, Cai J, Jia R, et al. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19. Emerg Microbes Infect. 2020;9(1):1254-1258.

36. Bell S, Clarke R, Moumier-Jack S, Walker JL, Paterson P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: Amulti-methods study in England. Vaccine. 2020;38(49):7789-7798.

37. Goldman RD, Yan TD, Seiler M, et al. Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey. Vaccine. 2020;38(48):7668-7673.

38. Zhang KC, Fang Y, Cao H, et al. Parental Acceptability of COVID-19 vaccination for children under the age of 18 years: cross-sectional online survey. JMIR Pediatr Parent. 2020;3(2):e24827.

39. Jeffs E, Lucas N, Walls T. COVID-19: Parent and caregiver concerns about reopening New Zealand schools. J Paediatr Child Health. 2021;57(3):403-408.

40. Yigit M, Ozkaya-Parlakay A, Sene1 E. Evaluation of COVID-19 vaccine refusal in parents. Pediatr Infect Dis J. 2021;40(4):e134-e136.

41. Goldman RD, Staubli G, Cotanda CP, et al. Factors associated with parents’ willingness to enroll their children in trials for COVID-19 vaccination. Hum Vacc Immunother. 2021;17(6):1607-1611.

42. Whitley A. Global surge in measles and major international survey reinforce the need for greater awareness and uptake of all vaccinations. Acta Paediatr. 2020;109(9):1706-1708.

43. Li X, Mukandavire C, Cucunuba ZM, et al. Estimating the health direct effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet. 2021;397(10272):398-408.

44. Robertson T, Carter ED, Chou VB, et al. Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study. Lancet Glob Health. 2020;8(7):e901-e908.

45. Commissioners W-U-L. After COVID-19, a future for the world's children? Lancet. 2020;396(10247):298-300.
46. Ludvigsson JF. Children are unlikely to be the main drivers of the COVID-19 pandemic - A systematic review. Acta Paediatr. 2020;109(8):1525-1530.
47. Kao CM, Orenstein WA, Anderson EJ. The importance of advancing SARS-CoV-2 vaccines in children. Clin Infect Dis. 2021;72(3):515-518.
48. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020;396(10263):1614-1616.
49. Aschwanden C. Five reasons why COVID herd immunity is probably impossible. Nature. 2021;591(7851):520-522.
50. INED database on COVID-19 deaths by age and sex. Data & metadata. 2021. Accessed April 9. https://dc-covid.site.ined.fr/en/data/
51. Ministry of Health. COVID-19: Case demographics. 2021. Accessed April 18, 2021. https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-data-and-statistics/covid-19-case-demographics#age-gender
52. Epidemiology Working Group for Ncip Epidemic Response CCfDC, Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Chinese Journal of Epidemiology. 2020;41(2):145-151.
53. Doroftei B, Ciobica A, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics (Basel). 2021;11(4):579.
54. Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric receptor binding domain-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials Lancet Infect Dis. 2021;21(8):1107-1119. [published online ahead of print March 24, 2021].
55. Blumenthal KG, Robinson LB, Camargo CA Jr, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562-1565.
56. Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021;325(21):2201-2202.
57. Gavi. The COVID-19 vaccine race-weekly update. 2021. Accessed April 14, 2021. https://www.gavi.org/vaccineswork/covid-19-vaccine-race
58. Health Horizon. In June this year, China’s vaccination rate is expected to reach 40%, a report on the approval of many new coronavirus vaccine. 2021. Accessed March 2, 2021. https://mp.weixin.qq.com/s?src=11&timestamp=1626965716 &ver=3206&signature=UyhB5rj3QXBoDM4JkAdWscVmSYv DiKeR46ktLHR"KznhX40kXq52TZ9bM3AcUW0um6OS*QzSwr BqRj2H8"rtCF-p5aQAZXa7uR4YX145eD7MWO3tdN9reJb5RP n&new=1
59. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
60. Palacios R, Batista AP, Albuquerque CSN, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV Study (April 11, 2021). Available at SSRN: https://ssrn.com/abstract=3822780 or http://dx.doi.org/10.2139/ssrn.3822780

How to cite this article: She J, Liu L, Liu W. Providing children with COVID-19 vaccinations is challenging due to lack of data and wide-ranging parental acceptance. Acta Paediatr. 2022;111:35–44. https://doi.org/10.1111/apa.16137